Last edition
News about "Teva"
Duvakitug Shows Durable Efficacy in Ulcerative Colitis and Crohn's Disease in Long-Term Study
Long-term extension data show sustained remission and endoscopic response with duvakitug in ulcerative colitis and Crohn’s disease, strengthening its position as a potential next-generation TL1A therapy.
Teva | 18/02/2026 | By News Bureau | 149
Teva secures EC approval for two denosumab biosimilars, Ponlimsi and Degevma
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., has received marketing authorizations from the European Commission for its two denosumab biosimilars—Ponlimsi, referencing Prolia, and Degevma, referencing Xgeva.
Teva | 27/11/2025 | By Darshana | 154
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy